Key insights
- Hims & Hers Health is exploring peptides as a potential growth driver as the market for compounded GLP-1 drugs evolves. The stock has seen a 25% increase since discussions surrounding peptides emerged. However, clinical evidence for peptide efficacy is limited, and FDA review is in early stages, with a key meeting scheduled for July 2026. This presents a speculative bullish signal for HIMS, but with significant regulatory uncertainty.
Hims stock price growth 25% since the peptide meeting day is set
KEY POINTS
- Investors are starting to focus on what will replace compounded GLP-1 as a growth driver for telehealth companies like Hims & Hers Health. * Peptides are gaining attention as a potential new growth vector, despite clinical evidence for efficacy being limited. * The FDA review process is only just beginning, with a Pharmacy Compounding Advisory Committee meeting scheduled for July 2026.
Full link: https://www.cnbc.com/amp/2026/04/16/rfk-jr-peptides-hims-hers-glp-1.html